Literature DB >> 9765157

Transition from moderate to excessive drug intake: change in hedonic set point.

S H Ahmed1, G F Koob.   

Abstract

Differential access to cocaine self-administration produced two patterns of drug intake in rats. With 1 hour of access per session, drug intake remained low and stable. In contrast, with 6 hours of access, drug intake gradually escalated over days. After escalation, drug consumption was characterized by an increased early drug loading and an upward shift in the cocaine dose-response function, suggesting an increase in hedonic set point. After 1 month of abstinence, escalation of cocaine intake was reinstated to a higher level than before. These findings may provide an animal model for studying the development of excessive drug intake and the basis of addiction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765157     DOI: 10.1126/science.282.5387.298

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  481 in total

1.  The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Authors:  Laura Orio; Sunmee Wee; Amy H Newman; Luigi Pulvirenti; George F Koob
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  Alterations in AMPA receptor subunits and TARPs in the rat nucleus accumbens related to the formation of Ca²⁺-permeable AMPA receptors during the incubation of cocaine craving.

Authors:  Carrie R Ferrario; Jessica A Loweth; Mike Milovanovic; Kerstin A Ford; Gregorio L Galiñanes; Li-Jun Heng; Kuei Y Tseng; Marina E Wolf
Journal:  Neuropharmacology       Date:  2011-01-27       Impact factor: 5.250

3.  AUTOMATED ANALYSIS OF QUANTITATIVE IMAGE DATA USING ISOMORPHIC FUNCTIONAL MIXED MODELS, WITH APPLICATION TO PROTEOMICS DATA.

Authors:  Jeffrey S Morris; Veerabhadran Baladandayuthapani; Richard C Herrick; Pietro Sanna; Howard Gutstein
Journal:  Ann Appl Stat       Date:  2011-01-01       Impact factor: 2.083

4.  Changes in response to a dopamine receptor antagonist in rats with escalating cocaine intake.

Authors:  Serge H Ahmed; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2003-11-28       Impact factor: 4.530

5.  Striatal cell type-specific overexpression of DeltaFosB enhances incentive for cocaine.

Authors:  Christina R Colby; Kim Whisler; Cathy Steffen; Eric J Nestler; David W Self
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

6.  Escalated cocaine "binges" in rats: enduring effects of social defeat stress or intra-VTA CRF.

Authors:  Michael Z Leonard; Joseph F DeBold; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2017-07-18       Impact factor: 4.530

7.  Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving.

Authors:  Florence R Theberge; Xuan Li; Sarita Kambhampati; Charles L Pickens; Robyn St Laurent; Jennifer M Bossert; Michael H Baumann; Mark R Hutchinson; Kenner C Rice; Linda R Watkins; Yavin Shaham
Journal:  Biol Psychiatry       Date:  2013-02-04       Impact factor: 13.382

8.  Variability of drug self-administration in rats.

Authors:  Leigh V Panlilio; Jonathan L Katz; Roy W Pickens; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2003-03-18       Impact factor: 4.530

9.  Continuous intracerebroventricular infusion of the competitive NMDA receptor antagonist, LY235959, facilitates escalation of cocaine self-administration and increases break point for cocaine in Sprague-Dawley rats.

Authors:  Richard M Allen; Kristina A Uban; Elizabeth M Atwood; David S Albeck; Dorothy J Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-07-21       Impact factor: 3.533

10.  Once is too much: conditioned aversion develops immediately and predicts future cocaine self-administration behavior in rats.

Authors:  Elizabeth M Colechio; Caesar G Imperio; Patricia S Grigson
Journal:  Behav Neurosci       Date:  2014-04       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.